Galderma announced a major milestone when the Swedish Medical Products Agency approved an update to the pharmaceutical manufacturing certification.
This approval follows a successful inspection of Galderma's manufacturing facility in Uppsala, Sweden, for Good Manufacturing Practices (GMP), enabling Galderma to manufacture and perform biological testing of RelabotulinumtoxinA (QM1114), the latest innovation in the Botulinum Toxin A class of fillers.
RelabotulinumtoxinA (QM1114) is a new generation of water-based filler researched and developed by Galderma using proprietary PEARL™ technology, which helps maintain the molecular structure for high efficiency and no clumping. It is another important development in Galderma's Injectable Aesthetics R&D program.
“Our commitment to leading innovation in dermatology is reflected in our high-performance operations. These new license updates granted by the Swedish authorities reflect Galderma's skills and the capacities we are building to support our rapid growth trajectory. As we work to extend our category leadership globally, these new capabilities will increase Galderma's autonomy to manufacture and commercialize the next generation of scientifically differentiated innovations in dermatology.”
“Our commitment to leading skin innovation is reflected in our high-performance operations. The new license update received from the Swedish authorities reflects Galderma’s skills and the capabilities we are building to support our rapid growth trajectory as we work to expand our category leadership globally. These new capabilities will further enhance Galderma’s independence to manufacture and commercialize the next generation of scientifically differentiated dermatology innovations.”
ADRIAN MURPHY
HEAD OF GLOBAL OPERATIONS
GALDERMA
Read more at: https://www.galderma.com/
Photo credit: https://www.galderma.com/sites/default/files/styles/news_main/public/Website_Thumbnail.jpg
